<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01307111</url>
  </required_header>
  <id_info>
    <org_study_id>HRRC #09-426</org_study_id>
    <nct_id>NCT01307111</nct_id>
  </id_info>
  <brief_title>Misoprostol Prior to Intrauterine Device (IUD) Insertion in Nulliparous Women</brief_title>
  <official_title>A Randomized Control Trial of Misoprostol Versus Placebo for Cervical Priming in IUD Insertion for Nulliparous Women</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of New Mexico</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of New Mexico</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to see if using misoprostol makes the intrauterine device
      insertion easier and less painful in women who have never had a baby.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The Intrauterine Device (IUD) is an excellent contraceptive option because of its ease of
      use, long term duration (5-10 years), low side-effect profile, and the immediate return to
      fertility after IUD removal. Despite advantages associated with the IUD, the smaller cervical
      diameter of nulliparous patients may lead to a more difficult and uncomfortable insertion.
      Some providers have started pre-medicating nulliparous patients with misoprostol prior to IUD
      insertion because of the drug's known effect as a cervical ripening agent. Limited evidence
      is available addressing the effect of misoprostol on patient comfort and provider ease of IUD
      insertion in nulliparous women. The goal of this study is to evaluate whether using
      misoprostol as a cervical ripening agent in nulliparous patients eases IUD insertion and
      decreases pain.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2011</start_date>
  <completion_date type="Actual">March 2013</completion_date>
  <primary_completion_date type="Actual">February 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Patient Perceived Pain on a 100-point Visual Analogue Scale.</measure>
    <time_frame>Prior to insertion, immediately after insertion, and prior to clinic discharge.</time_frame>
    <description>Perceived pain was registered on a 100-point visual analogue scale (0 = no pain, 100 = worst pain imaginable) at three time points: prior to IUD insertion, immediately after insertion, and prior to clinic discharge.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Provider Perceived Ease of Insertion on a 100-point Visual Analogue Scale.</measure>
    <time_frame>Immediately post IUD insertion</time_frame>
    <description>Perceived ease of IUD insertion registered on a visual analogue scale (0 = easy, 100 = extremely difficult).</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">85</enrollment>
  <condition>Pain</condition>
  <arm_group>
    <arm_group_label>Misoprostol</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Misoprostol 400 micrograms inserted buccally or vaginally, per the participants desire.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Pills which are identical to the study drug in appearance, taste, and smell.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Misoprostol</intervention_name>
    <description>400 micrograms inserted buccally or vaginally, per the participants desire prior to the IUD insertion.</description>
    <arm_group_label>Misoprostol</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Pills which are identical to the study drug in appearance, taste, and smell.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  14 years old or older

          -  Negative pregnancy test

          -  No prior pregnancies lasting beyond 19 6/7 weeks

          -  Minimum 2 weeks after spontaneous or medical abortion

          -  Minimum 4 weeks post 2nd trimester or surgical abortion

          -  No previous IUD insertions

          -  No PID in last 3 months

          -  No current cervicitis

          -  Willing to follow-up in 1-2 months for an IUD string check

        Exclusion Criteria:

          -  Active cervical infection

          -  Current pregnancy

          -  Prior pregnancy beyond 19 6/7 weeks gestation

          -  Known uterine anomaly

          -  Fibroid uterus distorting uterine cavity

          -  Copper allergy/Wilson's Disease (for Paragard)

          -  Undiagnosed abnormal uterine bleeding

          -  Cervical or uterine cancer
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>14 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Eve Espey, MD/MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of New Mexico Department of Obstetrics and Gynecology</affiliation>
  </overall_official>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <verification_date>February 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 1, 2011</study_first_submitted>
  <study_first_submitted_qc>March 1, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 2, 2011</study_first_posted>
  <results_first_submitted>December 16, 2015</results_first_submitted>
  <results_first_submitted_qc>March 9, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">March 28, 2016</results_first_posted>
  <last_update_submitted>March 9, 2016</last_update_submitted>
  <last_update_submitted_qc>March 9, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 28, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of New Mexico</investigator_affiliation>
    <investigator_full_name>Eve Espey</investigator_full_name>
    <investigator_title>Professor, OB-GYN</investigator_title>
  </responsible_party>
  <keyword>Misoprostol</keyword>
  <keyword>IUD insertion</keyword>
  <keyword>Nulliparous Women</keyword>
  <keyword>Contraception</keyword>
  <keyword>Family Planning</keyword>
  <keyword>IUD insertion in nulliparous women</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Misoprostol</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>The study design is double-blind randomized controlled trial in which nulliparous women requesting an IUD were randomized to 400 mcg of buccal misoprostol or placebo 2-8 hours before insertion.</recruitment_details>
      <pre_assignment_details>3 of the 85 enrolled participants were deemed ineligible and not randomized to misoprostol or the placebo group.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Misoprostol</title>
          <description>Misoprostol 400 micrograms inserted buccally or vaginally, per the participants desire.
Misoprostol: 400 micrograms inserted buccally or vaginally, per the participants desire prior to the IUD insertion.</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Pills which are identical to the study drug in appearance, taste, and smell.
Placebo: Pills which are identical to the study drug in appearance, taste, and smell.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>IUD Insertion</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="42"/>
                <participants group_id="P2" count="40"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="40"/>
                <participants group_id="P2" count="40"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>1-2 Week IUD Check up</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="40"/>
                <participants group_id="P2" count="40"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="38"/>
                <participants group_id="P2" count="38"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>IUD expulsion/removal</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Misoprostol</title>
          <description>Misoprostol 400 micrograms inserted buccally or vaginally, per the participants desire.</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Pills which are identical to the study drug in appearance, taste, and smell.</description>
        </group>
        <group group_id="B3">
          <title>Not Randomized</title>
          <description>Women not eligible to continue to randomization.</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="42"/>
            <count group_id="B2" value="40"/>
            <count group_id="B3" value="3"/>
            <count group_id="B4" value="85"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="24.1" spread="4.3"/>
                    <measurement group_id="B2" value="24.1" spread="4.6"/>
                    <measurement group_id="B3" value="NA">Patient data not collected, deemed ineligible after recruitment.</measurement>
                    <measurement group_id="B4" value="24.1" spread="4.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="42"/>
                    <measurement group_id="B2" value="40"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="42"/>
                    <measurement group_id="B2" value="40"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Secondary</type>
        <title>Provider Perceived Ease of Insertion on a 100-point Visual Analogue Scale.</title>
        <description>Perceived ease of IUD insertion registered on a visual analogue scale (0 = easy, 100 = extremely difficult).</description>
        <time_frame>Immediately post IUD insertion</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Misoprostol</title>
            <description>Misoprostol: 400 micrograms inserted buccally or vaginally, per the participants desire prior to the IUD insertion.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo: Pills which are identical to the study drug in appearance, taste, and smell.</description>
          </group>
        </group_list>
        <measure>
          <title>Provider Perceived Ease of Insertion on a 100-point Visual Analogue Scale.</title>
          <description>Perceived ease of IUD insertion registered on a visual analogue scale (0 = easy, 100 = extremely difficult).</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
                <count group_id="O2" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.2" spread="2.2"/>
                    <measurement group_id="O2" value="2.5" spread="2.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Patient Perceived Pain on a 100-point Visual Analogue Scale.</title>
        <description>Perceived pain was registered on a 100-point visual analogue scale (0 = no pain, 100 = worst pain imaginable) at three time points: prior to IUD insertion, immediately after insertion, and prior to clinic discharge.</description>
        <time_frame>Prior to insertion, immediately after insertion, and prior to clinic discharge.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Misoprostol</title>
            <description>Misoprostol: 400 micrograms inserted buccally or vaginally, per the participants desire prior to the IUD insertion.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo: Pills which are identical to the study drug in appearance, taste, and smell.</description>
          </group>
        </group_list>
        <measure>
          <title>Patient Perceived Pain on a 100-point Visual Analogue Scale.</title>
          <description>Perceived pain was registered on a 100-point visual analogue scale (0 = no pain, 100 = worst pain imaginable) at three time points: prior to IUD insertion, immediately after insertion, and prior to clinic discharge.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
                <count group_id="O2" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Pain perceived prior to insertion</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.5" spread="1.2"/>
                    <measurement group_id="O2" value="0.8" spread="1.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pain perceived immediately after insertion</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.8" spread="2.0"/>
                    <measurement group_id="O2" value="5.9" spread="2.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pain perceived prior to clinic discharge</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.2" spread="2.2"/>
                    <measurement group_id="O2" value="3.8" spread="2.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Misoprostol</title>
          <description>Misoprostol: 400 micrograms inserted buccally or vaginally, per the participants desire prior to the IUD insertion.</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Placebo: Pills which are identical to the study drug in appearance, taste, and smell.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Eve Espey, MD, MPH, Principle Investigator</name_or_title>
      <organization>University of New Mexico</organization>
      <phone>505-272-6372</phone>
      <email>eespey@salud.unm.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

